On or around 03/14/2007 (Court's order of dismissal)
Filing Date: June 16, 2006
On March 14, 2007 the judge ordered the case be dismissed without prejudice noting that the case should be removed from the docket "in light of the fact that [the] Plaintiff had failed to serve the Defendants within 120 days as required by Rule 4(m), and in light of the fact that for a period of more than 90 days Plaintiff had failed to take steps to move the case forward." The plaintiff filed an opposition brief on March 18, 2007 but has not filed a new complaint against Antigenics, Inc. or its individual officers.
The purported class action complaint was filed in the United States District Court for the District of New Mexico against Antigenics Inc. (the "Company") and its chief executive officer. The complaint alleges that certain disclosures by the Company violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 as well as includes purported claims for breach of fiduciary duty. The Company believes that the complaint is without merit and plans to vigorously defend against the litigation. The Company's policy is to not discuss pending litigation. Antigenics is a biotechnology company working to develop treatments for cancers, infectious diseases and autoimmune disorders.
Company & Securities Information
Defendant: Antigenics Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: AGEN
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Steven J. Tuckfelt, et al. v. Antigenics Inc., et al.
COURT: D. New Mexico
DOCKET #: 06-CV-00519
JUDGE: Hon. Judith C. Herrera
DATE FILED: 06/16/2006
CLASS PERIOD START: 09/03/2003
CLASS PERIOD END: 03/23/2006
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Ron Bell & Associates 610 7th Street NW, Ron Bell & Associates, NM 87102 505.242.7979 505.243.7192 ·
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violations of Federal Securities Laws - Jury Trial Demanded